Skip to main content
Fig. 2 | Cancer Communications

Fig. 2

From: Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience

Fig. 2

Subgroup analysis of the 3-year survival rate of patients with stage III colon cancer grouped by modified XELOX and unfinished XELOX according to T stage, N stage, and risk stratification. a Subgroup analysis of the 3-year disease-free survival rate. b Subgroup analysis of the 3-year overall survival rate. XELOX oxaliplatin and capecitabine regimen, HR hazard ratio, CI confidence interval

Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us